Available Trials

• Bladder
• Breast
• Cholangiocarcinoma
• Endometrial
• Gynecological/Ovarian
• Hematology
• Leukemia
• Lung - Non-Small Cell Lung
• Lymphoma
• Multiple Myeloma
• Pancreas
• PNH
• Solid Tumor
• Urothelial

Bladder

• USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

  Available at: Arlington Heights

  ---

Breast

• NOW OPEN - HER2+ Breast Trial USOR 19054: A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)

  Available at: Arlington Heights, Niles

  ---

Cholangiocarcinoma

• USOR 18264: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations. The PROOF Trial (QBGJ398-301)

  Available at: Arlington Heights, Niles

  ---

Endometrial

• NOW OPEN! USOR 19221: A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) D9311C00001; GOG-3041; ENGOT-EN10

  Available at: Arlington Heights, Niles

  ---

Gynecological/Ovarian

• USOR 19200 A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)(MIRASOL)

  Available at: Arlington Heights, Niles

  ---

Hematology

• USOR 18130 INCB 39110-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309.)

  Available at: Niles

  ---

Leukemia

• NOW OPEN! USOR 19205 ULTRA-V: A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

  Available at: Arlington Heights, Niles

  ---

• USOR 18155 A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL.) (BGB-3111-305)

  Available at: Arlington Heights, Niles

  ---

• AGIOS AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age and Older, with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.

  Available at: Niles, Arlington Heights

  ---

Lung - Non-Small Cell Lung

• USOR 19018: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE) Mirati 516-005

  Available at: Arlington Heights, Niles

  ---

• USOR 19192 A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)

  Available at: Arlington Heights, Niles

  ---

• USOR 19044: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative Non-Small Cell Lung Cancer. (D9103C00001)(PACIFIC-4/RTOG-3515)

  Available at: Niles

  ---

Lymphoma

• USOR 16065 Relapsed/Refractory - A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma. (UTX-TGR-205)

  Available at: Niles, Arlington Heights

  ---

• USOR 11282 A Phase 2, Open-Label Study, of Brentuximab Vedotin for Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above.(SGN35-015)

  Available at: Niles

  ---

• USOR 16100 Hodgkins Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices. (CA20965)

  Available at: Niles, Arlington Heights

  ---

Multiple Myeloma

• NOW OPEN! USOR 19247 A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

  Available at: Arlington Heights, Niles

  ---

Pancreas

• USOR 17160 / PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Testing Fields (TTFields, 150kHz) concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (EF-27)

  Available at: Niles, Arlington Heights

  ---

PNH

• USOR 08160 PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

  Available at: Niles, Arlington Heights

  ---

Solid Tumor

• USOR 19079 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)

  Available at: Arlington Heights, Niles

  ---

Urothelial

• USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

  Available at: Arlington Heights

  ---